SCHEMBL1446643

SCHEMBL1446643

O=C(O)c1ccc(NCc2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.70
CA2 P00918 2/20 0.70
FFAR1 O14842 3/20 0.62
FFAR4 Q5NUL3 1/20 0.62
HIF1A Q16665 3/20 0.60
ALDH1A1 P00352 2/20 0.60
POLB P06746 2/20 0.60
HPGD P15428 1/20 0.60
HSD17B10 Q99714 1/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
HDAC3 O15379 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC2 Q92769 1/20 0.59
NCOR2 Q9Y618 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
HTT P42858 1/20 0.58
MRGPRX4 Q96LA9 1/20 0.56
MAPT P10636 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14044007 0.93 FFAR1 (0.69) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL5211384 0.92 ALDH1A1 (0.65) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL4418236 0.92 CA1 (0.59) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL4748420 0.90 HIF1A (0.68) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL11257944 0.90 FFAR1 (0.71) CA1CA2FFAR1FFAR4ALDH1A1
SCHEMBL2742815 0.89 CA1 (0.70) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL11881329 0.87 CA1 (0.68) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL14043706 0.85 HIF1A (0.62) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL14043636 0.85 HIF1A (0.62) CA1CA2FFAR1FFAR4HIF1A
SCHEMBL14043916 0.85 FFAR1 (0.70) CA1CA2FFAR1FFAR4HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119053220-A Perovskite solar cell mini-module and preparation method thereof 武汉华鸣新能源有限公司 2024-11-29 CN claimed
US-20110313158-A1 Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2011-12-22 US claimed
WO-2010097815-A2 A TWO COMPONENT RECYCLABLE HETEROGENEOUS CATALYST, PROCESS FOR PREPARATION THEREOF AND ITS USE FOR PREPARATION OF AMINES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-09-02 WO claimed
WO-2025086591-A1 ROTIGOTINE PRODRUG DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 烟台药物研究所 2025-05-01 WO disclosed
CN-119053220-A Perovskite solar cell mini-module and preparation method thereof 武汉华鸣新能源有限公司 2024-11-29 CN disclosed
CN-117105906-B Rotigotine prodrug derivatives, pharmaceutical compositions and uses thereof 烟台药物研究所 2024-01-30 CN disclosed
CN-117105906-A Rotigotine prodrug derivatives, pharmaceutical compositions and uses thereof 烟台药物研究所 2023-11-24 CN disclosed
EP-4265613-A1 BENZENE RING COMPOUND AND USE THEREOF Nanjing Shijiang Medicine Technology Co., Ltd (CN) 2023-10-25 EP disclosed
CN-113321640-B Indole compound and application thereof 中国科学院广州生物医药与健康研究院 2023-06-09 CN disclosed
CN-109111427-B Indole compound and application thereof 中国科学院广州生物医药与健康研究院 2023-06-02 CN disclosed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-4362892-A ARALKYLANILINES, ANTICHOLESTEROL AGENTS BEECHAM GROUP LIMITED (GB) 1982-12-07 US disclosed
US-4350822-A Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives AMERICAN CYANAMID COMPANY (US) 1982-09-21 US disclosed
US-4246275-A Antilipidemic para-[thienyl and furyl (alkyl or alkenyl)amino]-benzoic acid derivatives AMERICAN CYANAMID COMPANY (US) 1981-01-20 US disclosed
US-4206145-A ALKANOYL-SUBSTITUTED ARALKYLAMINES BEECHAM GROUP LIMITED (GB) 1980-06-03 US disclosed
US-4185115-A Antilipidemic para-[aryl(alkyl or alkenyl)amino]-benzoic acid derivatives AMERICAN CYANAMID COMPANY (US) 1980-01-22 US disclosed
US-4181737-A 4-((3-Methoxyphenyl)amino)benzoic acid, a method for treating hyperlipidemia, and compositions thereof THE DOW CHEMICAL COMPANY (US) 1980-01-01 US disclosed
US-4178385-A Method for treating hyperlipidemia in primates using 4-((4-fluorophenylmethyl)amino)benzoic acid THE DOW CHEMICAL COMPANY (US) 1979-12-11 US disclosed
US-4133890-A Hypolipidemic compositions and method employing derivatives of 4-(((1,3-benzodioxol-5-yl)methyl)amino)benzoic acid THE DOW CHEMICAL COMPANY (US) 1979-01-09 US disclosed
US-4105791-A Hypolipidemic cycloalkylaminobenzoic acids THE DOW CHEMICAL COMPANY (US) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313158-A1 Two Component Recyclable Heterogeneous Catalyst, Process for Preparation Thereof and its Use for Preparation of Amines HCN2, RAC2, HCN1 CA1 1227/4885CA2 188/4885FFAR1 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.